BIONOTE e-nose technology may reduce false positives in lung cancer screening programmes

Raffaele Rocco, Raffaele Antonelli Incalzi, Giorgio Pennazza, Marco Santonico, Claudio Pedone, Isaura Rossi Bartoli, Chiara Vernile, Giuseppe Mangiameli, Antonello La Rocca, Giuseppe De Luca, Gaetano Rocco, Pierfilippo Crucitti

Research output: Contribution to journalArticlepeer-review


OBJECTIVES: Breath composition may be suggestive of different conditions. E-nose technology has been used to profile volatile organic compounds (VOCs) pattern in the breath of patients compared with that of healthy individuals. BIOsensor-based multisensorial system for mimicking NOse, Tongue and Eyes (BIONOTE) technology differs from Cyranose® based on a set of separate transduction features. On the basis of our previously published experience, we investigated the discriminating ability of BIONOTE in a high-risk population enrolled in a lung cancer screening programme. METHODS: One hundred individuals were selected for BIONOTE based on the attribution to the high-risk category (i.e. age, smoking status, chronic obstructive pulmonary disease status) of the University Campus Bio-Medico lung screening programme. We used a measure chain consisting of (i) a device named Pneumopipe (EU patent: EP2641537 (A1):2013-09-25) able to catch exhaled breath by an individual normally breathing into it and collect the exhalate onto an adsorbing cartridge; (ii) an apparatus for thermal desorption of the cartridge into the sensors chamber and (iii) a gas sensor array which is part of a sensorial platform named BIONOTE for the VOCs mixture analysis. Partial least square (PLS) has been used to build up the model, with Leave-One-Out cross-validation criterion. Each breath fingerprint analysis costs €10. RESULTS: The overall sensitivity and specificity were 86 and 95%, respectively, delineating a substantial difference between patients and healthy individuals. CONCLUSIONS: Our preliminary data show that BIONOTE technology may be used to reduce false-positive rates resulting from lung cancer screening with low-dose computed tomography in a cost-effective fashion. The model will be tested on a larger number of patients to confirm the reliability of these results.

Original languageEnglish
Article numberezv328
Pages (from-to)1112-1117
Number of pages6
JournalEuropean Journal of Cardio-thoracic Surgery
Issue number4
Publication statusPublished - Apr 1 2016


  • E-nose
  • Lung cancer
  • Screening

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery
  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'BIONOTE e-nose technology may reduce false positives in lung cancer screening programmes'. Together they form a unique fingerprint.

Cite this